Artivion (NYSE:AORT) SVP Sells $145,188.54 in Stock

Artivion, Inc. (NYSE:AORT) SVP Jean Holloway sold 3,843 shares of the firm’s stock in a transaction that occurred on Tuesday, March 3rd. The stock was sold at an average price of $37.78, for a total value of $145,188.54. Following the transaction, the senior vice president owned 194,057 shares in the company, valued at $7,331,473.46. This represents a 1.94% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.

Artivion Stock Performance

AORT traded down $0.21 during trading on Wednesday, hitting $38.41. 460,494 shares of the stock were exchanged, compared to its average volume of 509,518. The stock has a fifty day moving average price of $41.42 and a two-hundred day moving average price of $42.92. Artivion, Inc. has a 1-year low of $21.97 and a 1-year high of $48.25. The firm has a market capitalization of $1.84 billion, a P/E ratio of 61.30 and a beta of 1.60. The company has a quick ratio of 2.62, a current ratio of 3.53 and a debt-to-equity ratio of 0.49.

Artivion (NYSE:AORT) last issued its quarterly earnings data on Thursday, February 12th. The company reported $0.17 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.14 by $0.03. The company had revenue of $118.30 million for the quarter, compared to the consensus estimate of $116.42 million. Artivion had a net margin of 2.21% and a return on equity of 7.43%. Artivion’s revenue was up 19.2% compared to the same quarter last year. As a group, sell-side analysts predict that Artivion, Inc. will post 0.37 earnings per share for the current year.

Analyst Ratings Changes

Several research firms have recently commented on AORT. Weiss Ratings upgraded shares of Artivion from a “sell (d)” rating to a “hold (c-)” rating in a research note on Friday, February 20th. Needham & Company LLC reaffirmed a “buy” rating and issued a $58.00 price objective on shares of Artivion in a report on Monday, February 2nd. Oppenheimer reissued an “outperform” rating and set a $50.00 target price on shares of Artivion in a research note on Friday, November 7th. Canaccord Genuity Group reduced their price target on Artivion from $51.00 to $48.00 and set a “buy” rating for the company in a report on Friday, February 13th. Finally, Wall Street Zen cut Artivion from a “buy” rating to a “hold” rating in a research report on Saturday, February 14th. Six equities research analysts have rated the stock with a Buy rating and two have issued a Hold rating to the stock. According to MarketBeat.com, Artivion has a consensus rating of “Moderate Buy” and an average price target of $48.97.

Institutional Investors Weigh In On Artivion

Several institutional investors and hedge funds have recently made changes to their positions in AORT. Verition Fund Management LLC increased its position in Artivion by 1.6% during the third quarter. Verition Fund Management LLC now owns 16,912 shares of the company’s stock worth $716,000 after buying an additional 274 shares in the last quarter. Entropy Technologies LP raised its holdings in Artivion by 6.0% in the 4th quarter. Entropy Technologies LP now owns 5,504 shares of the company’s stock valued at $251,000 after acquiring an additional 310 shares during the last quarter. State of Alaska Department of Revenue lifted its stake in shares of Artivion by 1.8% during the 3rd quarter. State of Alaska Department of Revenue now owns 23,294 shares of the company’s stock worth $985,000 after purchasing an additional 414 shares during the period. PNC Financial Services Group Inc. grew its position in shares of Artivion by 6.2% in the third quarter. PNC Financial Services Group Inc. now owns 8,232 shares of the company’s stock valued at $349,000 after purchasing an additional 477 shares during the period. Finally, Arizona State Retirement System grew its position in shares of Artivion by 4.6% in the fourth quarter. Arizona State Retirement System now owns 11,235 shares of the company’s stock valued at $512,000 after purchasing an additional 494 shares during the period. 86.37% of the stock is currently owned by hedge funds and other institutional investors.

Artivion News Summary

Here are the key news stories impacting Artivion this week:

• Positive Sentiment: Analysts remain constructive — consensus rating is “Moderate Buy” with several buy/outperform notes and mid‑to‑high price targets that support investor demand. Artivion Receives Consensus Rating
• Positive Sentiment: Management will present at the Oppenheimer Healthcare MedTech & Services Conference (virtual fireside chat), giving the company an opportunity to update investors on growth drivers, product progress and commercial milestones. Conferences can re‑ignite buying interest if guidance or pipeline commentary is favorable. Artivion to Participate in Oppenheimer Conference
• Positive Sentiment: Large institutional investors have been adding exposure (Invesco and others increased stakes), which can provide a steady bid and signals confidence from professional investors. MarketBeat – Artivion Institutional Activity
• Neutral Sentiment: Recent quarterly results beat revenue and EPS estimates and showed strong year‑over‑year revenue growth; that supports the bull case but may already be reflected in the share price and analyst upgrades. MarketBeat – Artivion Earnings Summary
• Negative Sentiment: Multiple senior insiders sold stock over March 2–4 (including the CEO and several EVPs/SVPs). A concentrated block of insider sales often weighs on sentiment even when executives retain large holdings — markets can interpret it as opportunistic liquidity or as a signal of limited near‑term confidence. Insider Trades Alert

About Artivion

Artivion, Inc (NYSE: AORT) is a global medical technology company that develops, manufactures and markets implantable tissue products and surgical devices for cardiac and vascular surgery. The company’s portfolio includes biologic implants derived from human and animal tissue, such as allografts and xenografts, as well as synthetic scaffolds and surgical adhesives. These products are designed to repair, reinforce or replace damaged cardiovascular and thoracic tissues during procedures such as aortic repair, heart valve surgery and vascular reconstruction.

Originally founded in 1984 under the name CryoLife, the company rebranded as Artivion in early 2022 to reflect its broader mission in cardiovascular innovation.